Certified by Founder
Lodge
AlgoTx
start up
France
- Suresnes, Ile-de-France
- 15/03/2023
- Series B
- $21,157,000
AlgoTx develops novel solutions for complex pain. Our lead program, ATX01, targets highly prevalent Chemotherapy-Induced Peripheral Neuropathy and the orphan disease erythromelalgia.
- Industry Biotechnology Research
- Website https://www.linkedin.com/company/algotx/about/
- LinkedIn https://www.linkedin.com/company/algotx/